Due to sparsity of data, ALK inhibitors are not usually the preferred option, probably due to extensive prior systemic therapies leading to accelerated tumour evolution, promoting growth of aggressive cell clones, resulting in diminished response to ALK inhibitors [20]. To fully evaluate their clinical potential, ALK inhibitors can probably be tried in therapy-naive patients. This evidence concerns the gene ALK and neoplasm.